📊 IPSC Key Takeaways
Is Century Therapeutics, Inc. (IPSC) a Good Investment?
Century Therapeutics is a pre-commercial biotech company with significant revenue growth but severe profitability challenges and deteriorating financial health. While exceptional revenue growth (+1556.8% YoY) and strong liquidity suggest successful commercialization, the company is burning cash at an unsustainable rate (-$104.7M FCF) with negative operating margins (-15.8%) and a widening cash burn runway despite asset base.
Century Therapeutics shows a headline revenue surge, but the business still generated negative operating income and deeply negative free cash flow, suggesting the top-line growth has not translated into durable profitability. The balance sheet is relatively strong with high liquidity and low leverage, but the current cash burn rate and weak cash conversion make the growth quality questionable and keep execution risk elevated.
Why Buy Century Therapeutics, Inc. Stock? IPSC Key Strengths
- Exceptional revenue growth of 1556.8% YoY indicates successful market entry and product adoption
- Strong balance sheet with $61.9M cash and minimal debt (0.07x debt-to-equity), providing runway
- Excellent liquidity position with 5.97x current ratio ensures no immediate solvency concerns
- Strong liquidity position with a 5.97x current ratio and $61.85M in cash
- Low leverage with debt/equity of 0.07x, limiting balance-sheet strain
- Large year-over-year revenue increase indicates meaningful business development or milestone activity
IPSC Stock Risks: Century Therapeutics, Inc. Investment Risks
- Massive operating cash burn of -$103.9M annually is unsustainable and will exhaust cash reserves within 6-8 quarters
- Company remains deeply unprofitable with negative operating margins (-15.8%) and operating losses of -$17.3M despite revenue growth
- Free cash flow of -$104.7M with -95.9% FCF margin demonstrates business model has not achieved unit economics or scaling efficiency
- Negative interest coverage (-32.0x) indicates inability to service debt from operations if liquidity deteriorates
- Operating cash flow of -$103.88M and free cash flow of -$104.72M indicate heavy ongoing cash burn
- Negative operating margin and net margin show the company remains fundamentally unprofitable
- Revenue growth quality may be low if driven by non-recurring collaboration or milestone payments rather than scalable recurring operations
Key Metrics to Watch
- Operating cash burn rate and cash runway timeline to profitability or funding needs
- Path to positive operating margins as revenue scales - currently growing revenue without profitability improvement
- Gross margin realization once available - critical to understanding long-term unit economics sustainability
- Quarterly operating cash burn relative to cash balance
- Revenue mix and repeatability of collaboration, milestone, or licensing revenue
Century Therapeutics, Inc. (IPSC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.97x current ratio provides a solid financial cushion.
IPSC Profit Margin, ROE & Profitability Analysis
IPSC vs Healthcare Sector: How Century Therapeutics, Inc. Compares
How Century Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Century Therapeutics, Inc. Stock Overvalued? IPSC Valuation Analysis 2026
Based on fundamental analysis, Century Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Century Therapeutics, Inc. Balance Sheet: IPSC Debt, Cash & Liquidity
IPSC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Century Therapeutics, Inc.'s revenue has grown significantly by 2,000% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.61 indicates the company is currently unprofitable.
IPSC Revenue Growth, EPS Growth & YoY Performance
IPSC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $791.0K | $9.6M | $0.11 |
| Q2 2025 | $771.0K | -$28.1M | $-0.38 |
| Q1 2025 | $855.0K | -$28.1M | $-0.45 |
| Q3 2024 | $148.0K | -$28.1M | $-0.37 |
| Q2 2024 | $99.0K | -$28.1M | $-0.38 |
| Q1 2024 | $855.0K | -$28.1M | N/A |
| Q3 2023 | $148.0K | -$30.7M | $-0.53 |
| Q2 2023 | $99.0K | -$31.0M | $-0.54 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Century Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
IPSC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Century Therapeutics, Inc. (CIK: 0001850119)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 10, 2026 | 4 | xslF345X06/form4-04102026_090449.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_110429.xml | View → |
| Mar 26, 2026 | 8-K | tm269823d1_8k.htm | View → |
| Mar 16, 2026 | 4 | xslF345X05/form4-03162026_080351.xml | View → |
| Mar 16, 2026 | 4 | xslF345X05/form4-03162026_080350.xml | View → |
❓ Frequently Asked Questions about IPSC
What is the AI rating for IPSC?
Century Therapeutics, Inc. (IPSC) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IPSC's key strengths?
Claude: Exceptional revenue growth of 1556.8% YoY indicates successful market entry and product adoption. Strong balance sheet with $61.9M cash and minimal debt (0.07x debt-to-equity), providing runway. ChatGPT: Strong liquidity position with a 5.97x current ratio and $61.85M in cash. Low leverage with debt/equity of 0.07x, limiting balance-sheet strain.
What are the risks of investing in IPSC?
Claude: Massive operating cash burn of -$103.9M annually is unsustainable and will exhaust cash reserves within 6-8 quarters. Company remains deeply unprofitable with negative operating margins (-15.8%) and operating losses of -$17.3M despite revenue growth. ChatGPT: Operating cash flow of -$103.88M and free cash flow of -$104.72M indicate heavy ongoing cash burn. Negative operating margin and net margin show the company remains fundamentally unprofitable.
What is IPSC's revenue and growth?
Century Therapeutics, Inc. reported revenue of $109.2M.
Does IPSC pay dividends?
Century Therapeutics, Inc. does not currently pay dividends.
Where can I find IPSC SEC filings?
Official SEC filings for Century Therapeutics, Inc. (CIK: 0001850119) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IPSC's EPS?
Century Therapeutics, Inc. has a diluted EPS of $-0.14.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IPSC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Century Therapeutics, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IPSC stock overvalued or undervalued?
Valuation metrics for IPSC: ROE of -6.0% (sector avg: 15%), net margin of -8.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IPSC stock in 2026?
Our dual AI analysis gives Century Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IPSC's free cash flow?
Century Therapeutics, Inc.'s operating cash flow is $-103.9M, with capital expenditures of $848.0K. FCF margin is -95.9%.
How does IPSC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -8.8% (avg: 12%), ROE -6.0% (avg: 15%), current ratio 5.97 (avg: 2).